Abstract Objective To investigate the effect of Alteplase on ultra early stage for clinical outcome of patients with cerebral infarction. Methods From October 2015 to December 2016, in Dongyang People's Hospital, 120 cerebral infarction patients were selected, they were divided into the observation group (60 cases) and control group (60 cases) by random number table, the control group was given routine treatment, the observation group was given Alteplase on ultra early stage based on the control group, two groups were treated for 14 d. Neuron specific enolase (NSE), central nerve specific protein (S100β) and inflammatory factor, neurological function, life ability and adverse reaction of two groups were compared. Results After treatment, the NSE and S100 in observation group were lower than those in control group, IL-6, TNF-a, CRP was lower than those in control group, the differences were statistically significant (P < 0.05). The MBI score in observation group was higher than that in control group, the NIHSS score was lower than that in control group, the differences were statistically significant (P < 0.05). There was no significant difference in adverse reactions between the two groups (P > 0.05). Conclusion Alteplase on ultra early stage can significantly reduce inflammatory factors, NSE and S100β level of patients with cerebral infarction, improve neurological function and life ability, and less adverse reactions, it is a safe and effective treatment method.
LI Hongfei XU Dongjuan ZHANG Weiqiang GUO Xiang. Effect of Alteplase on ultra early stage for clinical outcome of patients with cerebral infarction[J]. 中国医药导报, 2017, 14(14): 64-67.
